StockWireNews

Tiny Float (TCBP) Is A Nasdaq Profile With An Explosive Chart History (Multiple 100+% Intraday Runs In 2023)

January 16th

Greetings Readers,

We've got a minute, so let's chat.

My alert from this past Tuesday continued to move green all the way to Friday's closing bell.

Hitting a high of $5.03 Friday, it officially moved approximately 19% from its Tuesday open of $4.21.

Plus, when it hit a new 2-month high on Friday, we were able to crown another champ.

But that's not all...

January 4th's profile surged approximately 15% intraday.

December 30th's profile rocketed approximately 94% within a week.

December 28th's profile blasted approximately 20% in the span of 3 days.

See a pattern forming?

We've put together a strong run of breakout champs, but nothing may hold a torch to our next idea.

Based on a mind-blowing low float of fewer than 1Mn shares, an explosive chart history full of $1.00+ intraday blasts, and advancing testing of a lead drug candidate (dosed first three patients within Phase 2b clinical trial), this Nasdaq profile needs to be on your radar:

TC Biopharm (Holdings) Plc (Nasdaq: TCBP)

TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia.

And based on these potential catalysts, TCBP could be a near term breakout candidate. Check them out:

No. 1 - A Wildly Low Float Could Create Environment For Daily Volatility

No. 2 - A Super Explosive Chart History (See What Happened Friday?)

No. 3 - Key Milestone Achieved Within Phase 2b Clinical Trial

No. 4 - Another Amazing Achievement For Company's Lead Product OmnImmune®

But more on those in a second...

The Leading Gamma-Delta T-Cell Company

Vertically integrated operations, along with building exceptional teams and capabilities, allows TC BioPharm to move quickly, providing unique ability to rapidly respond to internal discovery and external factors.

Gamma Delta T Cells

The company's therapies are focused on leveraging the inherent biological capabilities of gamma delta T cells (GDT cells) together with an integrated cell engineering approach.

GDT cells are a component of the lymphocytes (white blood cells) present within all humans, representing approximately 1-5% of the circulating population. As part of the immune system's innate response, their natural properties make them promising therapeutic candidates.

This review demonstrates the historical work on GDT cell therapies, and the promise offered by combinations or modifying them with transgenes.

GDT cells constantly monitor the body for signs of biological stress, such as cancerous or infected cells, and are one of the first lines of defense against disease. They do this by detecting changes in the cells, mediated by a complex series of events, but the effect of which is common across all cancers and infections.

An analysis of gene expression from 18,000 individual tumors from 39 different malignancies showed that GDT cells were the infiltrating immune cells most likely to be associated with positive outcomes. Researchers have shown that there are various types of GDT cells, all with slightly differing properties.

At TC BioPharm, the company is fascinated by the power of all subtypes and are actively developing drugs based on the ethos of using the subtype which is best equipped to fight the particular disease.

Advantages of using GDT Cells as a Cell Therapy Vehicle

• They are naturally cytotoxic via a number of different mechanisms.
• They activate a wider immune response through antigen presentation and cytokine/chemokine release.
• They are completely safe for healthy cells and will not kill them, even when introduced at very high numbers.
• They are primed to infiltrate tissue, seeking sites of cellular stress and are biologically equipped to enter, reside and survive in a hostile tumor environment.
• The GDT cell receptor is not MHC-restricted. This means that if GDT cells from a donor are transferred to a patient, the GDT cells don’t recognize the patient’s body as foreign and don’t cause graft versus host disease (GvHD). This makes them ideal for allogeneic “off the shelf” therapies.
• They can be gathered from healthy donors, expanded to very high numbers, banked and frozen, using our validated GMP methods, providing a readily available starting material for manufacturing multiple products.

TC Biopharm Pipeline

Company Website. Company Presentation.

-----

And as I mentioned above, TCBP has multiple potential catalysts to know ahead of Tuesday's opening bell. Check them out:

No. 1 TCBP Potential Catalyst - A Wildly Low Float Could Create Environment For Daily Volatility

According to the Yahoo Finance website, TCBP has an incredibly low float.

The website reports this profile to have approximately 688.13K shares in its float.

Why is that important? It's important on one crucial level. Volatility.

Could positive company news early in 2023 provide a near term spark?

-----

No. 2 TCBP Potential Catalyst - A Super Explosive Chart History (See What Happened Friday?)

Can we talk about TCBP's 1-month chart?

That's bonkers. Follow me for a second.

In two separate occasions in 2023, TCBP has made single day moves of 100+%.

Crazy, I know. But the chart doesn't lie.

On January 4th, TCBP caught fire to run from an open of $4.38 to a high of $9.51.

That's 117% intraday.

On January 13th, TCBP erupted again running from an open of $4.79 to a high of $9.61.

That's 100% intraday.

Two separate situations of 100% runs in 2023... What could happen this week?

-----

No. 3 TCBP Potential Catalyst - Key Milestone Achieved Within Phase 2b Clinical Trial

TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating its Lead Compound, OmnImmune®, in Patients with Acute Myeloid Leukemia

• 3 Patients Dosed in 5 Patient Safety Cohort

EDINBURGH, Scotland, Nov. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer today announced the dosing of its first three patients within its Phase 2b clinical trial of OmnImmune®, an allogeneic unmodified cell therapy focused on treating Acute Myeloid Leukemia (AML).

The initial 5 patients in the trial are deemed a "safety cohort", spaced two weeks apart with safety review by an oversight board to confirm no drug related toxicity issues, subsequent to 5 patients being dosed the study will advance to open enrollment. This safety cohort is in line with TCBP's step-wise clinical trial advancement, moving from donor matching in the Phase 1b to a universal donor model with no HLA matching of donor to patient.

"The launch of our Phase 2B trial is a key milestone in the development of our lead therapeutic, OmnImmune®, for patients with AML and for TC BioPharm's emerging pipeline of 'off-the-shelf' gamma-delta T cell therapies," said Bryan Kobel, CEO of TC BioPharm. "This study design includes a 5 patient safety cohort prior to open enrollment, we expect to complete the safety cohort before the end of 2022. The next step in the study is a 19 patient interim review, which will allow TCBP to review dosing and increase dosing to a higher level should our team deem it necessary for efficacy, or we can elect to maintain our current dosing level of 7x10^7 or 700 million cells per dose. We look forward to moving ahead with our Phase 2b trial with a target for open enrollment in January 2023, as well as our efforts to expand our clinical efforts in the US in the first half of 2023."

TC BioPharm's Phase 2B trial, dubbed ACHIEVE, will enroll adults diagnosed with AML who have either relapsed or are refractory to prior treatments as well as a cohort for patients with myelodysplastic syndromes (MDS), conditions that can occur when the blood-forming cells in the bone marrow become abnormal. The trial is expected to enroll approximately 37 patients.

Read the full article here.

-----

No. 4 TCBP Potential Catalyst - Another Amazing Achievement For Company's Lead Product OmnImmune®

TC BioPharm Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune®

EDINBURGH, Scotland, Sept. 13, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer today announced that it has received approval from the UK regulatory body MHRA to apply an 18-month extrapolated shelf life to its current allogeneic cell therapy product, OmnImmune®.

This award enables TC BioPharm to ship and store sufficient product which can then be held cryopreserved at clinical sites to fulfill the requirements not only for its current Advanced Myeloid Leukemia trial ACHIEVE, but also for future clinical trials and eventually commercial treatment of patients. Additionally, TC BioPharm's in-house quality control department will continue to gather data in order to extend the shelf-life of OmnImmune®.

"The approval received from the MHRA for our frozen product is another very important piece of a complex jigsaw. It is indeed a further step towards the achievement of a platform to deliver truly off-the-shelf products in the cell therapy space. This milestone is a result of an incredible concerted effort from all the departments within TCB, including Product Development, Quality Control and Assurance, Production and Clinical. It is an exciting time to be working in this sector and I feel incredibly privileged and proud to be part of this amazing team at TC Biopharm."

Bryan Kobel, CEO, commented, "This MHRA approval of our freeze/thawed protocol for an 18-month shelf life is an encouraging step forward in TC BioPharm's developmental trajectory and further validation of the continuous effort and forward thinking of our development team. We are extremely pleased to receive MHRA approval for our Freeze/Thawed product, OmnImmune®, the first freeze/thawed gamma delta product in clinical trials. Being able to ship frozen gamma-delta T cells and deliver them clinics all around the world for storage and use in clinical trials as well as commercial treatment increases our economies of scale and our efficiency."

Kobel continued, "This approval brings OmnImmune® truly to the forefront as an "off the shelf" cell therapy, with the clinician's ability to bring product from the storage facility to the specialty pharmacy for thawing and deliver the therapeutic to the patient in a short window of time. We look forward to progressing our clinical trials in AML as well as other blood cancers and continue to evaluate partnering opportunities for our allogeneic gamma delta platform and advance our modified CAR gamma delta program."

Read the full article here.

-----

TCBP Recap - These Potential Catalyst Could Provide A Near Term Breakout Spark

No. 1 - A Wildly Low Float Could Create Environment For Daily Volatility

No. 2 - A Super Explosive Chart History (See What Happened Friday?)

No. 3 - Key Milestone Achieved Within Phase 2b Clinical Trial

No. 4 - Another Amazing Achievement For Company's Lead Product OmnImmune®

-----

Coverage is officially initiated on TCBP. When time permits, do this:

Get TCBP on your radar now.

Sincerely,

Kai Parker

StockWireNews

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)